TrivarX Limited
MDBIF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.07 | 0.13 | 0.02 |
| FCF Yield | -2.64% | 23.55% | -12.68% | -41.73% |
| EV / EBITDA | -22.86 | -28.03 | -6.27 | -6.32 |
| Quality | ||||
| ROIC | -3.58% | 4.75% | -10.33% | -12.91% |
| Gross Margin | 6,506.83% | 98.42% | -5.33% | -173.98% |
| Cash Conversion Ratio | 0.62 | -3.99 | -4.05 | 1.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 104.80% | 83.25% | -37.06% | -71.46% |
| Free Cash Flow Growth | -244.44% | 141.20% | 68.62% | -58.83% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | 18.46 | 0.85 | 0.24 |
| Interest Coverage | -57.04 | 21.54 | 2,397.99 | -78.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,223.38 | -3,099.25 | -1,821.37 | -1,035.28 |